Double-blinded randomised trial of prophylactic dexamethasone versus placebo in stereotactic radiotherapy to 1-5 brain metastases, assessing symptomatology and quality of life.

William Buckland Radiotherapy Centre0 个研究点目标入组 64 人开始时间: 2015年4月10日最近更新: 2022年8月9日

适应症

试验速览

暂无简介。

•1Number of brain metastases – 1-5 brain metastases (as defined on the MRI brain); at least one lesion planned for SRT
•2Non-primary brain tumour
•3ECOG performance status 0-2
•4Expected life expectancy of >6 months
•5Not on dexamethasone for at least 7 days preceding treatment
•6Willing or able to complete questionnaires by themselves
•7Willing to be contacted by the study investigators in first 30 days following treatment for follow up

•1More than 5 untreated brain metastases
•2Leptomeningeal metastases
•3Contraindications or comorbidities which may be seriously affected by dexamethasone – uncontrolled diabetes, previous psychosis secondary to dexamethasone
•4Inability to complete MRI
•5Planned cytotoxic chemotherapy during SRT
•6Other tumour types – primary germ cell tumour, small cell carcinoma, haematological malignancies
•7Brain metastases unsuitable for SRT (eg: located <2 mm of the optic chiasm)
•8Pregnant or lactating women
•9Men or women of childbearing potential who are unwilling to employ adequate contraception throughout study

发起方